×
For best experience we recommend to activate Javascript in your browser.
PIK3AP1 antibody (AA 489-730)
This Rabbit Polyclonal antibody specifically detects PIK3AP1 in WB and IHC. It exhibits reactivity toward Human.
Quick Overview for PIK3AP1 antibody (AA 489-730) (ABIN7624591)
Target
See all PIK3AP1 Antibodies
PIK3AP1
(phosphoinositide-3-Kinase Adaptor Protein 1 (PIK3AP1))
Reactivity
All reactivities for PIK3AP1 antibodies
Human
Host
All hosts for PIK3AP1 antibodies
Rabbit
Clonality
All clonalities for PIK3AP1 antibodies
Polyclonal
Conjugate
All conjugates for PIK3AP1 antibodies
This PIK3AP1 antibody is un-conjugated
Application
All applications for PIK3AP1 antibodies
Western Blotting (WB), Immunohistochemistry (IHC)
Product Details anti-PIK3AP1 Antibody
(hide)
Binding Specificity
All epitopes for PIK3AP1 antibodies
AA 489-730
Purpose
Phosphoinositide-3-Kinase Adaptor Protein 1 (PIK3AP1) Polyclonal Antibody
Sequence
Leu489~Ser730
Characteristics
The Phosphoinositide-3-Kinase Adaptor Protein 1 (PIK3AP1) Polyclonal Antibody (Species: Human) has been validated for the following applications: WB, IHC.
Purification
Antigen-specific affinity chromatography followed by Protein A affinity chromatography
Alternatives
(show)
Application Details
(hide)
Application Notes
Optimal working dilution should be determined by the investigator.
Restrictions
For Research Use only
Handling
(hide)
Format
Liquid
Concentration
0.5 mg/mL
Buffer
0.01M PBS, pH 7.4, containing 0.05 % Proclin-300, 50 % glycerol
Preservative
ProClin
Precaution of Use
This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
4 °C,-20 °C
Storage Comment
2°C to 8°C for frequent use, -20°C for 12 months. Avoid repeated freeze/thaw cycles.
Expiry Date
12 months
Target Details for PIK3AP1
(hide)
Target
PIK3AP1
(phosphoinositide-3-Kinase Adaptor Protein 1 (PIK3AP1))
Alternative Name
PIK3AP1
Gene ID
118788
UniProt
Q6ZUJ8
Pathways
Activation of Innate immune Response , BCR Signaling , Warburg Effect
Recently viewed
(hide)
Chat with us , powered by LiveChat